Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication

Psychiatry Research - Neuroimaging

Volumn 221, Issue 1, 2014, Pages 6-12

  Hutcheson, Nathan L ^a   Clark, David G ^b   Bolding, Mark S ^b,c   White, David M ^a   Lahti, Adrienne C ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b The University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Basal ganglia; Caudate; Magnetic resonance imaging (MRI); Risperidone; Schizophrenia; Treatment response

Indexed keywords

RISPERIDONE;

ADULT; AGE DISTRIBUTION; ARTICLE; BASAL GANGLION; BRAIN REGION; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; DEMOGRAPHY; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; GLOBUS PALLIDUS; HUMAN; MALE; MENTAL PATIENT; MIDDLE AGED; PRIORITY JOURNAL; PUTAMEN; SCHIZOPHRENIA; SYMPTOM; TREATMENT RESPONSE;

BASAL GANGLIA; CAUDATE; MAGNETIC RESONANCE IMAGING (MRI); RISPERIDONE; SCHIZOPHRENIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; BASAL GANGLIA DISEASES; CAUDATE NUCLEUS; FEMALE; GLOBUS PALLIDUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGAN SIZE; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84891827487     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2013.10.002     Document Type: Article

References (54)

1. Andreasen N.C., Pressler M., Nopoulos P., Miller D., Ho B.C. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biological Psychiatry 2010, 67:255-262.
2. Bartkó G., Frecska E., Horváth S., Zádor G., Arató M. Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients. Acta Psychiatrica Scandinavica 1990, 82:408-412.
3. Benes F.M., Paskevich P.A., Davidson J., Domesick V.B. The effects of haloperidol on synaptic patterns in the rat striatum. Brain Research 1985, 329:265-273.
4. Bora E., Fornito A., Radua J., Walterfang M., Seal M., Wood S.J., Yücel M., Velakoulis D., Pantelis C. Neuroanatomical abnormalities in schizophrenia: a multimodal voxelwise meta-analysis and meta-regression analysis. Schizophrenia Research 2011, 127:46-57.
5. Breier A., Buchanan R.W., Elkashef A., Munson R.C., Kirkpatrick B., Gellad F. Brain morphology and schizophrenia: a magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Archives of General Psychiatry 1992, 49:921-926.
6. Buchsbaum M.S., Shihabuddin L., Brickman A.M., Miozzo R., Prikryl R., Shaw R., Davis K. Caudate and putamen volumes in good and poor outcome patients with schizophrenia. Schizophrenia Research 2003, 64:53-62.
7. Chakos M.H., Lieberman J.A., Bilder R.M., Borenstein M., Lerner G., Bogerts B., Wu H., Kinon B., Ashtari M. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. American Journal of Psychiatry 1994, 151:1430-1436.
8. Chakos M., Lieberman J., Alvir J., Bilder R., Ashtari M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 1995, 345:456-457.
9. Chan R.C., Di X., McAlonan G.M., Gong Q.Y. Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression. Schizophrenia Bulletin 2011, 37:177-188.
10. Chua S.E., Deng Y., Chen E.Y., Law C.W., Chiu C.P., Cheung C., Wong J.C., Lienenkaemper N., Cheung V., Suckling J., McAlonan G.M. Early striatal hypertrophy in first-episode psychosis within 3 weeks of initiating antipsychotic drug treatment. Psychological Medicine 2009, 39:793-800.
11. Conley R.R., Buchanan R.W. Evaluation of treatment-resistant schizophrenia. Schizophrenia Bulletin 1997, 23:663-674.
12. Crespo-Facorro B., Pelayo-Terán J.M., Pérez-Iglesias R., Ramírez-Bonilla M., Martínez-García O., Pardo-García G., Vázquez-Barquero J.L. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. Journal of Psychiatric Research 2007, 41:659-666.
13. Cuesta M.J., Peralta V., De Leon J. Schizophrenic syndromes associated with treatment response. Progress in Neuropsychopharmacology and Biological Psychiatry 1994, 18:87-99.
14. De Peri L., Crescini A., Deste G., Fusar-Poli P., Sacchetti E., Vita A. Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: a meta-analysis of controlled magnetic resonance imaging studies. Current Pharmaceutical Design 2012, 18:486-494.
15. Ebdrup B.H., Glenthøj B., Rasmussen H., Aggernaes B., Langkilde A.R., Paulson O., Lublin H., Skimminge A., B., Baaré W. Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. Journal of Psychiatry and Neuroscience 2010, 35:95-104.
16. Ebdrup B.H., Norbak H., Borgwardt S., Glenthoj B. Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review. Current Medicinal Chemistry 2013, 20:438-447.
17. Ebdrup B.H., Skimminge A., Rasmussen H., Aggernaes B., Oranje B., Lublin H., Baaré W., Glenthøj B. Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. International Journal of Neuropsychopharmacology 2011, 14:69-82.
18. Ellison-Wright I., Glahn D.C., Laird A.R., Thelen S.M., Bullmore E. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. American Journal of Psychiatry 2008, 165:1015-1023.
19. Fornito A., Yücel M., Patti J., Wood S.J., Pantelis C. Mapping grey matter reductions in schizophrenia: an anatomical likelihood estimation analysis of voxel-based morphometry studies. Schizophrenia Research 2009, 108:104-113.
20. Fusar-Poli P., Radua J., McGuire P., Borgwardt S. Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM Studies. Schizophrenia Bulletin 2012, 38:1297-1307.
21. Geerts H., Spiros A., Roberts P., Twyman R., Alphs L., Grace A.A. Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response. PLoS One 2012, 7:e49732.
22. Ghafari E., Fararouie M., Shirazi H.G., Farhangfar A., Ghaderi F., Mohammadi A. Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia. Clinical Schizophrenia & Related Psychoses 2013, 6:172-176.
23. Glahn D.C., Laird A.R., Ellison-Wright I., Thelen S.M., Robinson J.L., Lancaster J.L., Bullmore E., Fox P.T. Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis. Biological Psychiatry 2008, 64:774-781.
24. Haijma S.V., Van Haren N., Cahn W., Koolschijn P.C.M.P., Hulshoff Pol H.E., Kahn R.S. Brain volumes in schizophrenia: a meta-analysis in over 18,000 subjects. Schizophrenia Bulletin 2012, 39(5):1129-1138.
25. Jablensky A., Sartorius N., Ernberg G., Anker M., Korten A., Cooper J.E., Day R., Bertelsen A. Schizophrenia manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine 1992, 22:1-97.
26. Keck P.E., Wilson D.R., Strakowski S.M., McElroy S.L., Kizer D.L., Balistreri T.M., Holtman H.M., DePriest M. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. Journal of Clinical Psychiatry 1995, 56:466-470.
27. Kerns J.M., Sierens D.K., Kao L.C., Klawans H.L., Carvey P.M. Synaptic plasticity in the rat striatum following chronic haloperidol treatment. Clinical Neuropharmacology 1992, 15:488-500.
28. Keshavan M., Bagwell W., Haas G., Sweeney J., Schooler N., Pettegrew J. Changes in caudate volume with neuroleptic treatment. Lancet 1994, 344:1434. (1434).
29. Kippin T.E., Kapur S., van der Kooy D. Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. Journal of Neuroscience 2005, 25:5815-5823.
30. Konradi C., Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biological Psychiatry 2001, 50:729-742.
31. Leung M., Cheung C., Yu K., Yip B., Sham P., Li Q., Chua S., McAlonan G. Gray matter in first-episode schizophrenia before and after antipsychotic drug treatment. Anatomical likelihood estimation meta-analyses with sample size weighting. Schizophrenia Bulletin 2011, 37:199-211.
32. Li M., Chen Z., Deng W., He Z., Wang Q., Jiang L., Ma X., Wang Y., Chua S.E., Cheung C., McAloan G.M., Sham P.C., Collier D.A., Gong Q., Li T. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment. Psychological Medicine 2011, 42:1475-1483.
33. McEvoy J.P., Schooler N.R., Wilson W.H. Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacology Bulletin 1991, 27:97-101.
34. Meshul C.K., Casey D.E. Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Research 1989, 489:338-346.
35. Molina V., Hernández J.A., Sanz J., Paniagua J.C., Hernández A.I., Martín C., Matías J., Calama J., Bote B. Subcortical and cortical gray matter differences between Kraepelinian and non-Kraepelinian schizophrenia patients identified using voxel-based morphometry. Psychiatry Research: Neuroimaging 2010, 184:16-22.
36. Molina V., Martín C., Ballesteros A., Herrera A.S., Hernández-Tamames J. Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics. European Archives of Psychiatry and Clinical Neuroscience 2011, 261:407-416.
37. Molina V., Reig S., Pascau J., Sanz J., Sarramea F., Gispert J.D., Luque R., Benito C., Palomo T., Desco M. Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia. Psychiatry Research: Neuroimaging 2003, 124:163-175.
38. Navari S., Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychological Medicine 2009, 39:1763-1777.
39. Nurnberger J.I., Blehar M.C., Kaufmann C.A., York-Cooler C., et al. Diagnostic Interview for Genetic Studies: rationale, unique features, and training. Archives of General Psychiatry 1994, 51:849-859.
40. Okugawa G., Nobuhara K., Takase K., Saito Y., Yoshimura M., Kinoshita T. Olanzapine increases grey and white matter volumes in the caudate nucleus of patients with schizophrenia. Neuropsychobiology 2007, 55:43-46.
41. Olabi B., Ellison-Wright I., McIntosh A.M., Wood S.J., Bullmore E., Lawrie S.M. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biological Psychiatry 2011, 70:88-96.
42. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychological Reports 1962, 10:799-812.
43. Randolph C. The repeatable battery for the assessment of neuropsychological status (RBANS): utility as an outcome measure in clinical trials for MCI and mild dementia. Alzheimer's & Dementia: the Journal of the Alzheimer's Association 2010, 6:486-487.
44. See R.E., Chapman M.A., Meshul C.K. Comparison of chronic intermittent haloperidol and raclopride effects on striatal dopamine release and synaptic ultrastructure in rats. Synapse 1992, 12:147-154.
45. Seeman M.V. Psychopathology in women and men: focus on female hormones. American Journal of Psychiatry 1997, 154:1641-1647.
46. Steen R.G., Mull C., McClure R., Hamer R.M., Lieberman J.A. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. British Journal of Psychiatry 2006, 188:510-518.
47. Thambisetty M., Simmons A., Velayudhan L., Hye A., Campbell J., Zhang Y., Wahlund L.O., Westman E., Kinsey A., Güntert A., Proitsi P., Powell J., Causevic M., Killick R., Lunnon K., Lynham S., Broadstock M., Choudhry F., Howlett D.R., Williams R.J., Sharp S.I., Mitchelmore C., Tunnard C., Leung R., Foy C., O'Brien D., Breen G., Furney S.J., Ward M., Kloszewska I., Mecocci P., Soininen H., Tsolaki M., Vellas B., Hodges A., Murphy D.G., Parkins S., Richardson J.C., Resnick S.M., Ferrucci L., Wong D.F., Zhou Y., Muehlboeck S., Evans A., Francis P.T., Spenger C., Lovestone S. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Archives of General Psychiatry 2010, 67:739-748.
48. Uranova N.A., Orlovskaya D.D., Apel K., Klintsova A.J., Haselhorst U., Schenk H. Morphometric study of synaptic patterns in the rat caudate nucleus and hippocampus under haloperidol treatment. Synapse 1991, 7:253-259.
49. van den Oord E.J.C.G., Adkins D.E., McClay J., Lieberman J., Sullivan P.F. A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophrenia Research 2009, 107:13-21.
50. Vita, A., De Peri, L., Deste, G., Sacchetti, E., 2012. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Translational Psychiatry 2,1-13.
51. Wang H.D., Dunnavant F.D., Jarman T., Deutch A.Y. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 2004, 29:1230-1238.
52. Westman E., Muehlboeck J.S., Simmons A. Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion. NeuroImage 2012, 62:229-238.
53. Winkler A.M., Kochunov P., Blangero J., Almasy L., Zilles K., Fox P.T., Duggirala R., Glahn D.C. Cortical thickness or grey matter volume? The importance of selecting the phenotype for imaging genetics studies. NeuroImage 2010, 53:1135-1146.
54. Woods B.T., Ward K.E., Johnson E.H. Meta-analysis of the time-course of brain volume reduction in schizophrenia: implications for pathogenesis and early treatment. Schizophrenia Research 2005, 73:221-228.